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Abstract
The Acne-Specific Quality of Life Questionnaire (Acne-QoL) was developed to measure the impact of facial
acne across four dimensions of patient quality of life. The main objective of the current study was to
evaluate the responsiveness of this instrument. Secondarily, this study provided an opportunity to extend
the developer’s psychometric validation. The Acne-QoL was utilized in two randomized, double-blind,
placebo-controlled studies of the efficacy of Estrostep (norethindrone acetate/ethinyl estradiol) in the
treatment of facial acne; a total of 296 Estrostep and 295 placebo patients were evaluated. The Acne-QoL
was completed at the beginning, middle (cycle 3), and end (cycle 6) of the 6-month treatment period. The
responsiveness of the Acne-QoL was demonstrated through its ability to detect both small (baseline to mid-
study) and moderate (baseline to study end) treatment advantages for Estrostep patients. Confirmatory
factor analysis supported the subscale structure, and internal consistency estimates were excellent. Con-
vergent and discriminant validity were supported by correlations between Acne-QoL scores and clinical
measures that were both in the direction and relative magnitude hypothesized. Finally, item response theory
analyses confirmed that each item is highly related to its subscale’s latent construct and that each subscale is
sensitive across a broad range of the underlying continuum. The results of this evaluation confirm that the
Acne-QoL is responsive, internally consistent, and valid.
Key words: Acne vulgaris, Facial dermatoses, Psychometrics, Quality of life, Skin diseases
Abbreviations: Acne-QoL – Acne-Specific Quality of Life Questionnaire; AGFI – Adjusted-Goodness-of-
Fit Index; CFI – Comparative Fit Index; FAGA – Facial Acne Global Assessment; GFI – Goodness-of-Fit
Index; IRT – item response theory; mg – milligrams; lg – micrograms; QoL – quality of life; RMSEA –
Root Mean Square Error of Approximation
Introduction
Acne vulgaris is a common skin condition that
affects approximately 17 million Americans,
causing both distress and disfigurement [1]. While
acne is most common in adolescence, it is also
prevalent among adults and can lead to lifelong
scarring. In addition to its substantial physical
effects, facial acne has been associated with a range
of psychosocial effects that impact health-related
quality of life, including anxiety, depression, self-
consciousness, embarrassment, low self-esteem,
and social withdrawal [2–4].
In the past, much of the literature on acne has
been devoted to the clinical assessment of acne in
terms of lesion counts or severity classifications,
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and treatment outcomes have been assessed
through global improvement ratings (provided by
either the dermatologist or patient). Neither se-
verity nor global measures, however, are designed
to detect changes in a patient’s health-related
quality of life. Although generic quality of life in-
struments are preferable in some situations, dis-
ease-specific measures have greater power to detect
change by focusing on aspects of functioning that
are most affected by the disease and tend to be of
greatest importance to patients [5]. To measure
health-related quality of life among patients with
facial acne, therefore, a new questionnaire, the
Acne-Specific Quality of Life Questionnaire (Acne-
QoL), was developed and validated for use in
clinical trials [6–8].
This report describes the first assessment of the
responsiveness of the Acne-QoL in placebo-con-
trolled clinical trials and provides further psycho-
metric validation.
Methods
The development and validation of the Acne-QoL
has been described in detail elsewhere [6–8].
Briefly, the Acne-QoL is a patient-completed
questionnaire with a 1-week recall period com-
posed of 19 items in four subscales: Self-Per-
ception, Role-Emotional, Role-Social, and Acne
Symptoms. Table 1 provides a summary of the
instrument’s content, and the full questionnaire is
provided by Martin et al. [8] Instrument scoring is
accomplished by summing the responses within the
subscales to yield four overall domain scores,
where higher scores indicate more favorable
quality of life.
The Acne-QoL was included in two similarly
designed, randomized, double-blind, placebo-con-
trolled, parallel-group, multicenter studies of the
efficacy and safety of Estrostep (norethindrone
acetate/ethinyl estradiol) on moderate acne vulg-
aris [9]. Estrostep is an oral contraceptive pill
combining low-dose phasic ethinyl estradiol (20,
30, and 35 lg for 5, 7, and 9 days, respectively)
with a constant 1 mg dose of norethindrone ace-
tate. The protocols of the trials were identical,
except that in one trial, blood samples were col-
lected at selected sites to analyze androgen levels
and pharmacokinetics of ethinyl estradiol and
norethindrone acetate, and in the other trial,
photographs of subjects’ facial acne were taken at
selected sites. By combining the data from the two
trials, a total of 296 patients receiving Estrostep
and 295 placebo patients were evaluated.
Female subjects aged from 14 to 49 years, at
least 1 year postmenarche, with a baseline men-
strual cycle less than 42 days in duration, were
eligible for randomization if they had (1) moderate
facial acne (20–100 comedones and 20–65 inflam-
Table 1. Domain structure of the Acne-QoL
Self-Perception Role-Emotional Role-Social Symptoms




Bumps on your facea





Bumps full of pus on facea
Feeling self-conscious Concern about not looking
your best
Socializing a problem Scabbing from facial acnea




opposite sex a problem








All questions are framed to be disease specific (‘. . . because of your facial acne’).
The response options for all but three questions include: extremely, very much, quite a bit, a good bit, somewhat, a little bit, and not at
all.
a The response options for these questions include: extensive, a whole lot, a lot, a moderate amount, some, very few, and none.
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matory lesions, and no more than 5 nodules) and
had not adequately responded to topical anti-acne
therapy; and (2) agreed to avoid using any topical
or systemic acne treatment. Major exclusion cri-
teria consisted of other significant facial skin dis-
ease for which topical treatment would be required
during the study, significant endocrinopathy such
as marked hirsutism, evidence of severe androgen
excess (i.e., testosterone levels >150 ng/dL), or if
the patient was pregnant or nursing.
The efficacy of Estrostep was assessed through
changes in the number of acne lesions and a phy-
sician-completed Facial Acne Global Assessment
(FAGA) at each follow-up visit. The FAGA pro-
vides a global assessment of acne severity and was
completed by physicians before they performed the
lesion counts.1 Two supplemental measures were
completed by patients at study exit to examine
patients’ perceptions of treatment-related changes,
however neither of these measures were used in the
current psychometric evaluation In addition, the
Acne-QoL was completed by patients at the be-
ginning, middle (cycle 3), and end (cycle 6) of the 6-
month treatment period. The methodology and
results of these clinical trials are fully described in
Maloney et al. [9] and formed the basis for the
FDA’s approval of an acne indication for Estro-
step. These data were pooled for this submission
because there were no differences in study design,
no meaningful population differences, and the ef-
ficacy results were statistically indistinguishable [9].
For the current study the same (pooled) data
from these trials were utilized to assess the
responsiveness of the Acne-QoL within placebo-
controlled trials and secondarily to confirm pre-
vious psychometric validation of the Acne-QoL.
Missing item-level data were handled according to
developer recommendations [7]. Specifically, each
subscale score was computed only for patients who
answered three or more items within the domain.
If patients failed to answer one or two items within
a domain, responses for these items were imputed
through mean substitution prior to the computa-
tion of the subscale score. In addition, data ob-
tained at study exit for patients discontinuing
between visits were carried forward and included
in analyses involving the next visit. Using this
method, 231 Estrostep and 219 placebo patients
provided Acne-QoL data throughout the study. As
reported in Maloney et al. [9], the dropout rates
for this study were comparable to other placebo-
controlled acne studies and did not influence the
conclusions regarding QoL.
Responsiveness of the instrument was assessed
by evaluating treatment differences (as measured
by change in Acne-QoL scores from baseline) at
the middle and end of the study. Following a series
of repeated measures ANOVAs, effect size statis-
tics were computed to more fully elucidate this
issue. Specifically, Guyatt’s responsiveness statis-
tic, which is defined as the difference in average
change scores between the two treatment groups
divided by the standard deviation of change scores
in the placebo group, was calculated for each
subscale [10].
In addition to evaluating the responsiveness of
the Acne-QoL, the opportunity was taken to fur-
ther the developer’s validation of this instrument
[6–8]. First, the subscale structure of the instru-
ment was confirmed. Specifically, after utilizing
PRELIS Version 2.0 to obtain the polychoric
correlation and corresponding asymptotic covari-
ance matrices, confirmatory factor analysis of the
baseline Acne-QoL data was conducted in LIS-
REL Version 8.30 using weighted least squares
estimation [11]. Model fit was evaluated using the
Goodness-of-Fit Index (GFI), the Adjusted-
Goodness-of-Fit Index (AGFI), and the Compar-
ative Fit Index (CFI). Schumacker and Lomax
(1996) suggest that, for each of these goodness-of-
fit indices, values greater than 0.90 are desirable
[12]. Cronbach’s alphas were computed to assess
the internal consistency reliability of each Acne-
QoL subscale.
Additional evidence for the convergent and
discriminant validity of the instrument was then
gathered by correlating each of the four domain
scores with a range of clinical measures: some of
these clinical measures were theoretically related to
acne-specific QoL (e.g., lesion counts and FA-
GAs), while others were not (e.g., blood pressure
and heart rate). Implicit in the examination of the
relations between the Acne-QoL subscale scores
and the two clinical measures of acne severity, le-
sion counts and FAGAs, is the assumption that
1To complete the FAGA, physicians categorize patients’ facial
acne as one of the following: ‘absent, minimal, mild, mild to
moderate, moderate, marked or severe’. Each category is
defined in detail on the assessment form.
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acne-specific quality of life (QoL) and acne sever-
ity are related. Gathering support for convergent
validity then involves showing that the Acne-QoL
measures acne-specific QoL precisely enough to
demonstrate this relation. Because values of the
Acne-QoL increase with better QoL and the two
clinical measures increase with greater severity, it
was expected that the correlations between these
measures would be negative in sign. Moreover, it
was expected that these correlations would be
moderate rather than large in magnitude both
because the respondents differ between the two
types of measures (i.e., patient vs. clinician) and
because the constructs addressed by each measure,
while related, are not redundant.
Item response theory (IRT) fits statistical mo-
dels to item responses in order to examine the
properties of items and estimate latent traits for
individuals. Because the Acne-QoL utilizes ordinal
response categories, Samejima’s [13] graded re-
sponse model was applied to assess both the sen-
sitivity and discriminating ability of each item.
IRT item parameter estimates were obtained using
marginal maximum a posteriori estimation as im-
plemented in Multilog Version 6.0 [14], and each
of the four subscales was calibrated separately to
satisfy the assumption of unidimensionality.
Results
Descriptive analyses
The treatment groups in both trials were similar
with respect to demographic and clinical charac-
teristics at randomization (Table 2), with an
overall mean age of 24.1 years (range: 13–
48 years). The majority of the patients in both
groups were Caucasian (68%) and their mean
(±SD) baseline lesion counts were similar (Es-
trostep, 73.7 ± 25.9; placebo, 72.3 ± 27.7).
Descriptive statistics for all four Acne-QoL
subscales at each visit are reported in Table 3.
Overall, the pattern of these descriptive statistics
suggests an advantage for the patients who re-
ceived Estrostep (i.e., average scores for all four
subscales are higher for the Estrostep patients at
both the mid-study and final visits). Treatment
analysis results showed that Estrostep-treated
subjects experienced greater (statistically signifi-
cant) improvements in all four domains of the
Acne-QoL when compared with placebo-treated
subjects at cycle 3 and that these treatment ad-
vantages continued to increase throughout the
remainder of the study [9]. Additional work has







Mean (SD) 24.28 (7.56) 23.92 (7.42)
Race, N (%)
White/Caucasian 202 (68%) 202 (68%)
Black 38 (13%) 46 (16%)
Asian 18 (6%) 7 (2%)
Hispanic 30 (10%) 34 (12%)
Other 8 (3%) 6 (2%)
Total lesion count
Mean (SD) 73.68 (25.91) 72.26 (27.66)
Table 3. Descriptive subscale-level statistics for the Acne-QoL
Baseline visit Mid-study visit Last visit
N Mean SD N Mean SD N Mean SD
Estrostep
Self-Perception 292 15.15 7.9 263 20.08 7.7 232 23.05 6.7
Role-Emotional 292 13.79 7.8 263 18.60 7.9 232 21.61 7.5
Role-Social 292 15.50 6.8 262 18.76 6.1 231 20.62 5.1
Acne Symptoms 292 13.75 5.3 263 18.32 5.8 230 20.97 5.4
Placebo
Self-Perception 290 14.97 7.5 247 18.71 8.5 219 19.58 7.8
Role-Emotional 290 14.19 7.5 247 17.19 8.6 219 18.24 8.3
Role-Social 288 15.73 6.7 247 17.53 6.8 219 18.33 6.0
Acne Symptoms 287 14.10 5.3 247 16.84 5.9 219 18.37 5.8
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recently been completed which shows that these
statistically significant findings are also clinically
meaningful (manuscript in progress).
Responsiveness
In a series of repeated measures ANOVAs, statis-
tically significant interactions between visit (base-
line, mid-study, and last) and treatment group
(Estrostep vs. placebo) were observed for all
subscales (p < 0:0001), with larger improvements
in average Acne-QoL subscale scores for Estro-
step patients when compared to the placebo pa-
tients (see Figure 1). All contrasts also showed
statistically significant differences, except for the
comparison between scores at the baseline and
mid-study visit for the Self-Perception subscale.
These results imply that, while Acne-QoL subscale
scores improved for both sets of patients across the
course of the study, the Acne-QoL was sufficiently
sensitive to demonstrate that the Estrostep pa-
tients experienced significantly greater improve-
ments in all four acne-specific QoL domains than
patients in the placebo group.
As shown in Tables 4 and 5, values of Guyatt’s
responsiveness statistic ranged from 0.14 to 0.28
and 0.41 to 0.49 at the mid-study and final visits,
respectively. Using Cohen’s (1977) guideline for
effect-size interpretation,2 these values indicate
that the Acne-QoL is sufficiently responsive to
Figure 1. (a–d). Subscale mean scores at baseline, midpoint, and final visit. Higher scores on the Acne-QoL subscales indicate a higher
level of QoL. The group differences are significant for all subscales between the midpoint and the final visit (p < 0:0001). The standard
deviations are provided in parentheses.
2Cohen (1977) suggested that effect sizes near 0.20 represent
small effects, those near 0.50 represent moderate effects, and
those near 0.80 represent large effects [15].
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pick up small treatment advantages (for Estro-
step as compared to placebo) such as those found
between the baseline and mid-study visits, as well
as moderate treatment advantages, such as those
found between the baseline and final visits [15].
Taken together, these two sets of results provide
strong evidence for responsiveness within the
context of placebo-controlled trials.
Confirmatory psychometric analyses
Confirmatory factor analysis supported the sub-
scale structure previously identified by the devel-
opers. However, all four Acne-QoL subscales were
found to be highly correlated, particularly the Self-
Perception, Role-Emotional, and Role-Social
subscales (inter-factor correlations ranged from
0.91 to 0.97), and inter-factor correlations between
those three subscales and the Acne Symptoms
subscale were between 0.82 and 0.85. The majority
of the items produced high factor loadings (i.e.,
values close to 1), suggesting that they fit quite well
within their assigned subscales, and the values for
the goodness-of-fit indices provide further evi-
dence of appropriate model fit: 0.98 (GFI), 0.97
(AGFI), and 0.99 (CFI). The Root Mean Square
Error of Approximation (RMSEA) was 0.07,
slightly higher than the typically accepted 0.05
[11]. However, in light of the excellent goodness-
of-fit indices and high factor loadings, as well as
the results of prior testing, the domain structure
was supported.
Internal consistency (as measured by Cron-
bach’s a) ranged from 0.87 to 0.96 across the three
time-points for the Self-Perception, Role-Emo-
tional, and Role-Social subscales. As is common
for symptom-related subscales, the estimates were
slightly lower for the Acne Symptoms subscale
(range: 0.77–0.86). Using Streiner and Norman’s
(1995) guideline that Cronbach’s a for health-re-
lated scales should not be lower than 0.70, each of
the Acne-QoL subscales was shown to be inter-
nally consistent [16].
The modest negative correlations shown in the
first two columns of Table 6 support the convergent
validity of the Acne-QoL by demonstrating that
acne severity as reported by clinicians is associated
with acne-specific QoL as reported by patients.
Likewise, discriminant validity was supported by
the very low correlations obtained between the
Acne-QoL subscale scores and clinical measures
assumed to be unrelated to acne-specific QoL, such
as blood pressure, heart rate, and height (Table 6).
Item response theory analyses
The IRT models generally fit the data well: the
solutions converged easily, the parameter esti-
mates were plausible, and the standard errors were
generally very small.
Table 4. Mean change in Acne-QoL subscale scores and effect sizes between the baseline and mid-study visits
Subscale Estrostep Placebo Effect size
N Mean SD N Mean SD
Self-Perception 262 4.75 7.45 247 3.66 7.91 0.14
Role-Emotional 262 4.64 7.71 247 2.94 7.52 0.23
Role-Social 261 3.11 5.80 246 1.71 5.55 0.25
Acne Symptoms 262 4.47 5.59 245 2.84 5.86 0.28
Table 5. Mean change in Acne-QoL subscale scores and effect sizes between the baseline and final visits
Subscale Estrostep Placebo Effect size
N Mean SD N Mean SD
Self-Perception 231 7.95 8.77 219 4.50 8.38 0.41
Role-Emotional 231 8.04 9.33 219 4.01 8.14 0.49
Role-Social 230 5.09 6.66 218 2.51 5.85 0.44
Acne Symptoms 229 7.21 5.81 217 4.25 6.00 0.49
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A large slope (large a value) indicates that an
item is highly related to the construct underlying
the subscale and can be used to differentiate
among individuals. The item discriminations or a
parameters for each of the four Acne-QoL sub-
scales were generally quite high (only two were less
than 1.5), suggesting that every item was strongly
related to the latent constructs measured by the
subscales.
The threshold or b parameters serve to locate
the scale value of the item response on the un-
derlying z-score scale of the latent construct. The
threshold estimates or b parameters for each of
the four subscales generally cover a wide range of
the underlying continuum. For example, the
threshold estimates for the Self-Perception sub-
scale range from 2.40 to 2.36. Because the items
within each Acne-QoL subscale produce a wide
range of threshold estimates, they are appropriate
for distinguishing among individuals across all
plausible levels of the underlying continuum.
Discussion
The results of this study confirm that the subscale
configuration of the Acne-QoL is appropriate and
that the instrument is both valid and internally
consistent, as well as sensitive to change and ca-
pable of detecting treatment differences in clinical
trials. A prior study also showed good test–retest
reliability for the Acne-QoL [8].
While high correlations among the Self-Percep-
tion, Role-Emotional, and Role-Social subscales
suggest that it might be possible to combine these
subscales into one, yielding a more parsimonious
two-subscale configuration, in practice, patients’
subscale scores are not likely to be as highly re-
lated as the inter-factor correlations suggest. In
particular, the inter-factor correlations were ob-
tained through weighted least squares estimation
using the polychoric correlation and asymptotic
covariance matrices, which are based on the the-
oretical relations among the continuous latent
variables hypothesized to underlie each item. Al-
though this computational method is the gold
standard for confirmatory factor analyses involv-
ing ordinal items [11], it is likely to overestimate
the degree of inter-relatedness among the sub-
scales. Furthermore any change in the subscale
structure of the Acne-QoL should only be made if
it both improves the utility of the questionnaire
and is consistent with clinical considerations.
In a previous study, the Acne-QoL was found to
be responsive to changes in the severity of patients’
facial acne following usual care therapy [8]. Be-
cause the aforementioned study did not include a
control group, the current research was necessary
to confirm the responsiveness of the Acne-QoL
in the context of placebo-controlled randomized
clinical trials. Within these trials, the Acne-QoL
was sufficiently responsive to pick up both small
and moderate treatment advantages for the pa-
tients who received Estrostep as compared to
placebo. These findings confirm the utility of the
Acne-QoL for demonstrating the efficacy of new
acne medications in placebo-controlled clinical
trials. Just as the accumulation of additional
Table 6. Correlations between the four Acne-QoL subscale scores and five clinical measures (both related and unrelated to QoL)
Subscale Total lesion count FAGA Systolic blood pressure Heart rate Height
Mid-study visit
Self-Perception 0.27* 0.30* 0.01 0.02 0.05
Role-Emotional 0.28* 0.30* 0.00 0.04 0.09**
Role-Social 0.21* 0.24* 0.02 0.06 0.09**
Acne Symptoms 0.28* 0.37* 0.02 0.00 0.03
Last visit
Self-Perception 0.30* 0.36* 0.03 0.07 0.10**
Role-Emotional 0.29* 0.37* 0.06 0.07 0.14***
Role-Social 0.25* 0.32* 0.06 0.03 0.12***
Acne Symptoms 0.35* 0.44* 0.09 0.01 0.07
FAGA – Facial Acne Global Assessment.
* p < 0:0001; ** p < 0:05; *** p < 0:01.
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validation information in various populations and
settings is always beneficial, however, further
evaluation of this instrument’s responsiveness
would also be valuable.
The results of the IRT analyses indicated that
nearly every item is strongly related to the con-
struct underlying the subscale to which it belongs.
At the same time, because all the slope estimates
are similar within each subscale, no one item or
group of items seems to be dominant. These find-
ings suggest that an IRT-based scoring algorithm
(or any algorithm that would differentially weight
the items) is not likely to improve the precision of
these measurements substantially. Because a more
complex algorithm might also discourage the use
of the Acne-QoL, it is recommended that the
current scoring algorithm continue to be utilized.
In summary, the results of this study confirm
previous psychometric evaluations of the Acne-
QoL and demonstrate that the questionnaire is
sufficiently responsive to assess the humanistic
impacts of facial acne in a randomized clinical trial
of a therapeutic intervention for acne vulgaris.
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11. Jöreskog KG, Sörbom D. LISREL 8: User’s Reference
Guide. Chicago, Illinois: Scientific Software International,
Inc., 1996.
12. Schumacker RE, Lomax RG. A Beginner’s Guide to Struc-
tural Equation Modeling. Mahwah, NJ: Erlbaum, 1996.
13. Samejima F. Estimation of latent ability using a response
pattern of graded scores. Psychometric Monograph, 1969,
no. 17.
14. Thissen D. MULTILOGTM User’s Guide: Version 6.0.
Chicago, Illinois: Scientific Software International, Inc.,
1991.
15. Cohen J. Statistical Power Analysis for the Behavioral
Sciences. New York: Academic Press, 1977; 8.
16. Streiner DL, Norman GR. Health Measurement Scales: A
Practical Guide to Their Development and Use. 2nd ed.
New York: Oxford University Press, 1995; 65.
Address for correspondence: Sheri Fehnel, RTI Health Solu-
tions, Research Triangle Institute, 3040 Cornwallis Road, Re-
search Triangle Park, NC 27709-2194, USA
Phone: +1-919-541-7454; Fax: +1-919-541-7222
E-mail: sfehnel@rti.org
816
